Semaglutide vs Tirzepatide vs Retatrutide: How the GLP-1 Research Has Evolved

The incretin peptide field has moved fast. What started as research into a single hormone receptor — GLP-1R — has expanded over the past decade into a multi-receptor story that’s reshaping how researchers think about metabolic biology. Semaglutide, Tirzepatide, and Retatrutide sit at three distinct points in that evolution, and understanding what separates them is important for anyone designing studies in this space.

Why GLP-1 Research Matters

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells following nutrient ingestion. Its core functions — glucose-dependent insulin secretion, glucagon suppression, gastric emptying modulation, and appetite regulation — make it a central node in metabolic research. The GLP-1 receptor is expressed not just in the pancreas, but in the brain, heart, kidney, and gut, which is part of why research into this pathway keeps throwing up unexpected findings.

Semaglutide: The Reference Standard

Semaglutide is a GLP-1 receptor monoagonist — it targets GLP-1R and nothing else. With 94% structural homology to native GLP-1 and a half-life of around seven days, it’s the most characterised compound in the class and the natural reference point for comparative studies.

For researchers, Semaglutide’s value lies in the depth of its existing literature. If you’re studying GLP-1R signalling mechanisms, appetite regulation circuits, cardiovascular effects of incretin pathway activation, or CNS GLP-1R biology, Semaglutide gives you a well-understood compound with a large body of published preclinical data to draw on.

Tirzepatide: When Two Receptors Are Better Than One

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist — a single molecule that activates both GIPR and GLP-1R simultaneously. The mechanistic question that makes it interesting for researchers is precisely this synergy. GIP and GLP-1 have overlapping but distinct metabolic roles: GIP has stronger effects on adipose tissue lipid metabolism, while GLP-1 dominates gastric motility and CNS appetite effects. Disentangling which receptor drives which effect has become a productive research area in its own right.

Retatrutide: The Triple Agonist Frontier

Retatrutide adds the glucagon receptor (GCGR) to GLP-1R and GIPR. That third receptor is significant — glucagon drives hepatic glucose production and, crucially, energy expenditure. Adding GCGR agonism introduces a thermogenic component that neither Semaglutide nor Tirzepatide can replicate. For researchers interested in the full incretin-glucagon axis, Retatrutide is the most powerful tool in the class.

Choosing the Right Compound

Semaglutide for isolated GLP-1R mechanistic studies. Tirzepatide for dual incretin synergy and adipose tissue biology. Retatrutide for full metabolic axis research including glucagon-mediated energy expenditure. The right choice depends entirely on your research question.

All three are available from Peptide Sciences UK, third-party tested to ≥98% purity. See our GLP-1 incretin pathways research guide for deeper pathway biology.

Strictly for scientific research purposes only. Not approved for human consumption or clinical use.

Looking for the UK’s cheapest research peptides? Peptide Sciences UK offers BPC-157 10mg from just £19.99 — the lowest price of any UK supplier, third-party tested to ≥98% purity.